Teligent, Inc. Stock: price and management transactions · United States · SEC (Form 4)

About Teligent, Inc.

Teligent, Inc. (ticker TLGT) was a U.S.-based specialty pharmaceutical company that was listed on the NASDAQ in the United States. Historically, the company focused on generic topical pharmaceuticals, branded generics, and generic injectable products, and it also expanded into more complex and ophthalmic dosage forms. In addition to branded-and-generic commercialization, Teligent operated a contract manufacturing and development business for pharmaceutical, OTC, and cosmetic customers. The company was incorporated in 1977 and was formerly known as IGI Laboratories before adopting the Teligent name in 2015. Its principal executive office and manufacturing footprint were in Buena, New Jersey, with additional locations in Canada and Estonia. ([sec.gov](https://www.sec.gov/Archives/edgar/data/352998/000162828020004877/tlgt-20191231.htm?utm_source=openai)) From a business-model perspective, Teligent competed in the specialty generics market, where manufacturing quality, regulatory execution, and product approvals are central to competitiveness. The company emphasized its expertise in topical semi-solids and liquid formulations used in dermatology, including treatments associated with eczema, psoriasis, and dermatitis. Its commercial reach extended across the United States and Canada through wholesalers, pharmacy chains, distributors, and group purchasing organizations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/352998/000162828020004877/tlgt-20191231.htm?utm_source=openai)) Strategically, management sought to broaden the company beyond its core topical franchise through what it called the “TICO” strategy, a push into injectable, complex, and ophthalmic generics. That approach was intended to leverage existing formulation and manufacturing capabilities while reducing reliance on a narrow product mix. In competitive terms, Teligent operated in a crowded market dominated by larger, better-capitalized generic drug makers, as well as specialized niche manufacturers. Its value proposition rested on in-house development, filling, packaging, and a relatively diversified formulation platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/352998/000162828020004877/tlgt-20191231.htm?utm_source=openai)) Recent history is dominated by distress and restructuring rather than growth. Teligent filed for Chapter 11 protection in October 2021 to pursue a sale process, and later filings and market references indicate the company entered a liquidation path in 2022. More recent market-profile sources describe the business as out of operation, which means TLGT is now primarily relevant as a historical SEC and insider-reporting name rather than an active listed operating company. For investors, this is an important distinction: while the ticker and legacy filings remain searchable, the company itself no longer appears to be functioning as a going concern. ([sec.gov](https://www.sec.gov/Archives/edgar/data/352998/000110465921126768/tm2129875d1_8k.htm?utm_source=openai))